Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Optinose logo — company profile

Optinose

Founded 2010 United States Yardley, United States 146 employees Post Ipo Equity Total: $566.20M Biotechnology, Medical Devices +1

General Information

Company Name Optinose
Founded Year 2010
Location United States Yardley, United States +3
Founders / Decision Makers
Team member Team member
Employees 146
Industries Biotechnology, Medical Devices, Pharmaceutical
Funding Stage Post Ipo Equity
Social

Get notified when Optinose moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Optinose

Optinose is a specialty pharmaceutical company focusing on the development and commercialization of products for patients treated by ear, nose, and throat (ENT) and allergy specialists. Its flagship product, XHANCE®, uses a proprietary Exhalation Delivery System™ (EDS®) to deliver a corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The U.S. Food and Drug Administration (FDA) has already approved XHANCE for the treatment of nasal polyps and, if the pending supplement is approved, it could become the first FDA-approved drug therapy for chronic sinusitis. Established in 2000, Optinose is headquartered in the United States, with a workforce of 141 full-time employees. The company places a strong emphasis on its culture, driven by its core values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance, and Possibility Thinking. Optinose has recently received a $55.00M Post-IPO Equity investment on May 9, 2024 from D. E. Shaw & Co. and Nantahala Capital Management.

Taxonomy: pharmaceutical industry, ENT specialists, chronic rhinosinusitis, nasal polyps, FDA approval, Exhalation Delivery System, clinical trials, sNDA submission, drug therapy, employee management, company culture

Funding Rounds & Investors (10)

View All
Funding Stage Amount Investors Lead Investors Date
Post-IPO Equity •••••• 2 •••• •••• 09 May 2024
Post-IPO Equity •••••• - 21 Nov 2022
Post-IPO Debt •••••• 1 •••• •••• 12 Sep 2020
Post-IPO Equity •••••• - 21 Nov 2019
Post-IPO Debt •••••• 1
Investor
02 Jan 2018

View All 10 Funding Rounds

Optinose Alternatives & Competitors

Optinose vs
Bioheng Therapeutics
Bioheng Therapeutics United States

We are committed to exploring the frontier of cell therapy, with a focus on allogeneic CAR-T

12 employees
Optinose vs
CEBIOTEX
CEBIOTEX Spain

Providing solutions for patients with cancer by helping surgeons in their oncological interventions.

Equity Crowdfunding
8 employees
Biotechnology, Health Care
Compare Optinose vs CEBIOTEX
Optinose vs
Acer Therapeutics Inc.
Acer Therapeutics Inc. United States

Focused on the acquisition, development & commercialization of therapies for serious rare and life-t...

Post Ipo Debt
16 employees
Biotechnology, Health and Wellness
Compare Optinose vs Acer Therapeutics Inc.

FAQ About Optinose

We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizin...
Optinose was founded in 2010.
Optinose is headquartered in Yardley, United States.
Optinose operates in the following industries: Biotechnology, Medical Devices, Pharmaceutical.
Optinose has approximately 146 employees.
Optinose has completed 10 funding rounds, raising a total of $566.20M. The latest funding stage is Post Ipo Equity.
Top alternatives and competitors to Optinose include Bioheng Therapeutics, CEBIOTEX, Acer Therapeutics Inc.. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Optinose and Bioheng Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Optinose and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy

Book a demo 30 minutes